Piper Sandler Maintains Overweight on Verona Pharma, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Verona Pharma (NASDAQ:VRNA) and raises the price target from $31 to $36.
April 16, 2024 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on Verona Pharma and increases the price target to $36.
The upgrade in price target by a reputable analyst like Yasmeen Rahimi from Piper Sandler is a strong positive signal for Verona Pharma. It suggests confidence in the company's future performance and potential for stock price appreciation. Such endorsements often lead to increased investor interest and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100